Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports, Novo's new experimental obesity injectable, a cannabinoid receptor-1 (CB1) drug called monlunabant, was shown in a modestly-sized phase 2 trial to increase […]